tirzepatide orthostatic hypotension Diagnosis and treatment of Tirzepatide's Prediabetes and Hypertension Impact

L-, 15.00 ,

During the Super Bowl, telehealth platform Hims & Hers released a controversial ad calling out drugmakers that provide weight loss drugs priced for profits, not patients. It then proceeded to highlight its compounded GLP-1 offerings, calling them affordable, doctor-trusted and formulated in the USA. Shortly after, Novo Nordisk responded to the ad with its own Check before you inject campaign, highlighting the argument that patients should be wary of compounded GLP-1s given that they arent FDA-approved products

Find out with GlycanAge- the most accurate test of bio-age and wellness available

Eli Lilly, the manufacturer of the GLP-1 / GIP agonist tirzepatide (Mounjaro, Zepbound) has announced the development of bimagrumab (LY3985863), an injected monoclonal antibody that binds the activin/myostatin type II receptors ActRIIA and ActRIIB and blocks ligand binding

Because of this, these drugs are also characterized as GLP-1 receptor agonists (GLP-1 RA)

This stubborn weight gain is where weight loss medication like Mounjaro can help